Stocks › RGNX

REGENXBIO Inc.

RGNX·Nasdaq·United States United States·USD
$7.16
-0.02 (-0.28%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RGNX
REGENXBIO Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGNXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of RGNX by members of U.S. Congress · 2 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Peter WelchPeter WelchHouse · D · VT RGNXREGENXBIO Inc. · Stock Purchase
$1,001 - $15,000
Nov 14, 2019 Oct 22, 2019 Filing ↗
Peter WelchPeter WelchHouse · D · VT RGNXREGENXBIO Inc. · Stock Sale
$1,001 - $15,000
Nov 14, 2019 Nov 8, 2019 Filing ↗

Whale Activity

Position changes in RGNX reported for 2026-09-30 by 195 institutional filers
Increased: 74New: 33Held: 21Decreased: 39Closed: 22No prior filing: 6
  • Increased74
  • New33
  • Held21
  • Decreased39
  • Closed22
  • No prior filing6
FilerSharesValueChange
BlackRock, Inc.7.7M$57.8Mincreased
Redmile Group, LLC5.0M$38.0Mincreased
JPMORGAN CHASE & CO3.6M$26.5Mincreased
STATE STREET CORP3.2M$23.7Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC2.6M$19.9Mincreased
VANGUARD CAPITAL MANAGEMENT LLC2.5M$19.0Mincreased
PRICE T ROWE ASSOCIATES INC /MD/1.9M$14.5Mincreased
TWO SIGMA INVESTMENTS, LP1.9M$14.3Mincreased
MORGAN STANLEY1.8M$13.7Mdecreased
GOLDMAN SACHS GROUP INC1.7M$12.7Mincreased
GEODE CAPITAL MANAGEMENT, LLC1.6M$11.9Mincreased
AQR CAPITAL MANAGEMENT LLC1.4M$10.3Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by RGNX insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: 02025 Q12025 Q2: -20.6K2025 Q22025 Q3: -15.4K2025 Q32025 Q4: -20.8K2025 Q42026 Q1: -5,1242026 Q12026 Q2: -34.9K2026 Q22026 Q3: 63.7K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

766 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Malzahn CraigChief Technology Officer Tax withholding −234 $9.32 $2K Sep 1, 2026 Form 4 ↗
Chan MitchellChief Financial Officer Tax withholding −4,902 $9.32 $46K Sep 1, 2026 Form 4 ↗
Ciongoli Gregory AustinDirector Purchase +53.4K $9.36 $500K Aug 27, 2026 Form 4 ↗
Ciongoli Gregory AustinDirector Purchase +49.2K $9.14 $450K Aug 26, 2026 Form 4 ↗
Ciongoli Gregory AustinDirector Grant / award +15.4K $0.00 $0 Aug 25, 2026 Form 4 ↗
PAKOLA STEVEChief Medical Officer Tax withholding −7,468 $9.69 $72K Aug 1, 2026 Form 4 ↗
Christmas Patrick J.Chief Strategy & Legal Officer Tax withholding −4,699 $9.69 $46K Aug 1, 2026 Form 4 ↗
PAKOLA STEVEChief Medical Officer Sale −2,161 $13.64 $29K Jul 2, 2026 Form 4 ↗
PAKOLA STEVEChief Medical Officer Option exercise +2,161 $7.86 $17K Jul 2, 2026 Form 4 ↗
Simpson CurranChief Executive Officer · Director Tax withholding −6,818 $13.09 $89K Jul 1, 2026 Form 4 ↗
PAKOLA STEVEChief Medical Officer Sale −36.7K $12.86 $472K Jul 1, 2026 Form 4 ↗
PAKOLA STEVEChief Medical Officer Option exercise +36.7K $7.86 $289K Jul 1, 2026 Form 4 ↗
Simpson CurranChief Executive Officer · Director Grant / award +1,453 $10.18 $15K Jun 30, 2026 Form 4 ↗
PAKOLA STEVEChief Medical Officer Sale −19.6K $11.04 $216K Jun 29, 2026 Form 4 ↗
Bennett JeanDirector Grant / award +9,807 $0.00 $0 May 29, 2026 Form 4 ↗
Zachary JenniferDirector Grant / award +9,807 $0.00 $0 May 29, 2026 Form 4 ↗
Glucksmann AlexandraDirector Grant / award +9,807 $0.00 $0 May 29, 2026 Form 4 ↗
Fox Allan M.Director Grant / award +9,807 $0.00 $0 May 29, 2026 Form 4 ↗
Mills Kenneth T.Director Grant / award +9,807 $0.00 $0 May 29, 2026 Form 4 ↗
Tasse DanielDirector Grant / award +9,807 $0.00 $0 May 29, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding RGNX · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
2.0M$23.5M0.22%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.5M$17.9M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
1.3M$15.2M0.02%Jun 30, 2026
Nuveen Quant Small Cap Equity Fund
TIAA-CREF Funds
855.2K$8.3M0.20%Jul 31, 2026
JPMorgan Small Cap Growth Fund
JPMorgan Trust II
629.8K$7.5M0.29%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
564.5K$6.8M0.01%Jun 30, 2026
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND
VANGUARD HORIZON FUNDS
467.2K$5.6M0.18%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
527.9K$5.1M0.02%Jul 31, 2026
BlackRock Advantage Small Cap Core Fund
BlackRock Funds
537.0K$5.1M0.09%Aug 31, 2026
iShares Russell 2000 Growth ETF
iShares Trust
378.1K$4.5M0.03%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list RGNX's shares (CUSIP 75901B107), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 3.2M shares4.8%
    Nov 10, 2026 · ↗
  • JPMORGAN CHASE & CO.SCHEDULE 13G · passive (13G) · 3.6M shares5.3%
    Oct 13, 2026 · ↗
  • JPMORGAN CHASE & COSCHEDULE 13G/A · passive (13G) · 2.3M shares4.4%
    Jun 4, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 2.7M shares5.3%
    May 12, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming regenxbio as client
$0$250K$500K$750K$1.0M2023 Q1: $223K2023 Q2: $150K2023 Q3: $154K2023 Q4: $141K20232024 Q1: $15K20242025 Q3: $60K2025 Q4: $100K20252026 Q1: $180K2026 Q2: $180K2026 Q3: $160K2026
  • BGR GOVERNMENT AFFAIRSREGENXBIO INC. · 2026 Q4 · HCR—
    Filing ↗
  • THEGROUP DC, LLCREGENXBIO · 2026 Q3 · HCR$60K
    Filing ↗
  • DLA PIPER LLP (US)REGENXBIO INC. · 2026 Q3 · HCR, MED$40K
    Filing ↗
  • LMH STRATEGIC SOLUTIONSREGENXBIO INC. · 2026 Q3 · HCR, PHA$60K
    Filing ↗
  • THEGROUP DC, LLCREGENXBIO · 2026 Q2 · HCR$60K
    Filing ↗

Government Contracts

Federal awards to REGENXBIO Inc. · USAspending

No federal contract awards found for REGENXBIO Inc..

U.S. Patents

Recent USPTO applications naming REGENXBIO Inc.

No USPTO patent applications found for REGENXBIO Inc..

Annual Financials

From RGNX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$170.4M$83.3M$90.2M$112.7M$470.3M
Operating income-$161.2M-$233.3M-$268.1M-$262.9M$160.0M
Net income-$193.9M-$227.1M-$263.5M-$280.3M$127.8M
Diluted EPS-$3.76-$4.59-$6.02-$6.50$2.91
Operating cash flow-$124.0M-$173.1M-$218.4M-$207.5M$218.9M
Cash and equivalents$34.5M$57.5M$34.5M$97.0M$345.2M
Total assets$453.0M$466.0M$574.0M$833.3M$1.11B
Total liabilities$350.3M$206.3M$262.2M$317.1M$349.6M
Shareholders' equity$102.7M$259.7M$311.7M$516.2M$764.3M

As REGENXBIO Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 5, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in RGNX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeOct 16, 2026
    EDGAR ↗
  • 8-K · Items 1.01Material agreementSep 23, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeAug 25, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 24, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJul 20, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 8.01Shareholder vote · Other eventsJun 3, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 8.01, 9.01Results of operations · Reg FD disclosure · Other eventsMay 14, 2026
    EDGAR ↗

About REGENXBIO Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersROCKVILLE, MD
Former namesReGenX Biosciences, LLC